Rowland Thomas Andrew 4

What Happened
Rowland Thomas Andrew, SVP and Head — Established Brands at ANI Pharmaceuticals (ANIP), reported a sale of 4,772 shares on March 11, 2026. The shares were disposed at $74.91 each for a total value of $357,471. This was a sale (not a purchase); sales by insiders can be routine and do not by themselves signal company prospects.

Key Details

• Transaction date: 2026-03-11; Price: $74.91 per share; Total proceeds: $357,471.
• Transaction type: Reported as an open‑market or private sale (Form 4 lists "Open market or private sale").
• Shares owned after transaction: Not specified in the details provided here.
• Filing date: 2026-03-13 — filed within the typical 2‑business‑day window (timely).
• No 10b5‑1 plan, tax‑withholding, or other footnotes were reported in the summary provided.

Context
Insider sales are common for various reasons (diversification, personal liquidity, tax planning) and do not necessarily indicate negative views of the company. For retail investors, purchases are often considered stronger signals than routine sales; this single reported sale should be interpreted as factual disclosure rather than a directional recommendation.